Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kuros Biosciences ( (CH:KURN) ) has shared an update.
Kuros Biosciences is addressing media inquiries regarding the resignation of former Board member Albert Arp, who allegedly shared price-sensitive information with an unrelated third party. The company is conducting an internal investigation but assures that this issue does not affect its strategic direction, financial results, or operations.
The most recent analyst rating on (CH:KURN) stock is a Buy with a CHF32.50 price target. To see the full list of analyst forecasts on Kuros Biosciences stock, see the CH:KURN Stock Forecast page.
More about Kuros Biosciences
Kuros Biosciences is a company focused on discovering, developing, and delivering innovative biologic technologies. With operations in the United States, Switzerland, and the Netherlands, it is listed on the SIX Swiss Exchange. The company’s flagship product, MagnetOs, is an advanced bone graft used globally, known for its unique technology that stimulates bone growth without added cells or growth factors.
Average Trading Volume: 239,328
Technical Sentiment Signal: Buy
Current Market Cap: CHF867.1M
Learn more about KURN stock on TipRanks’ Stock Analysis page.